||Researchers at the University
of Pennsylvania School of Medicine have discovered
that a group of liver enzymes called proprotein convertases
(PCs) may be the key to raising levels of good cholesterol
||Several PC enzymes, called furin, PACE4,
and PCSK5A, disable another enzyme called endothelial lipase
by clipping off a piece of it and by activating its inhibitor,
an increased level of HDL-C in the blood.
||The study appears in the current issue
of Cell Metabolism.
(PHILADELPHIA) – Researchers at the University
of Pennsylvania School of Medicine have discovered that a group of liver enzymes called proprotein convertases (PCs) may be the key to raising levels
cholesterol (HDL-C). The pathway by which these proteins
are able to achieve an increase in HDL cholesterol involves another
enzyme that normally degrades HDL-C, and was also discovered at
Penn. The newly recognized relationship between these enzymes and
cholesterol represents another target for ultimately controlling
good cholesterol. The study appears in the current issue of Cell
“Several PC enzymes, called furin, PACE4, and PCSK5A, disable
another enzyme called endothelial lipase by clipping off a piece of it
and by activating its inhibitor,” says first author Weijun
Jin, MD, Research Assistant Professor of Pharmacology. “This promotes
an increased level of HDL-C in the blood.”
“We showed that mice engineered to express high levels of PCSK5A
had 50 percent higher HDL-C than control mice,” says senior author
Daniel J. Rader, MD, the Cooper/McLure Professor of Medicine and Associate
Director of the Institute for Translational
Medicine and Therapeutics at Penn.
Increased HDL-C is due to decreased endothelial lipase (EL) activity. “This
is encouraging because it suggests that either the PC or EL enzyme might
be targets for drug therapy to raise good cholesterol, an unmet medical
need in patients with low HDL-C,” says Rader. What’s more,
the increase in HDL-C was shown to promote reverse cholesterol transport,
the process by which HDL protects against heart
Low levels of HDL-C put people at risk for atherosclerosis, thereby
increasing the risk of heart
attack and stroke. Although this study was
performed in mice, humans have the same proprotein convertases and endothelial
lipase, and these enzymes are conserved in all vertebrates. Jin and Rader
expect that the same pathway for controlling HDL-C will apply to humans.
The next step is to study how the genes for the PCs, EL itself, and
EL’s inhibitor are regulated. In addition, Jin and Rader plan to
test whether variation in blood levels of PCs and EL activity in humans,
as well as genetic variation in their genes, is associated with variation
in HDL-C levels and heart disease risk.
“We hope to identify polymorphisms in the genes for PCs, EL, and
its inhibitor that are associated with HDL-C levels, thus supporting
that this pathway is relevant in humans,” says Rader.
Co-authors are Xun Wang, John S. Millar, and Jane M. Glick from Penn
Quertermous (Stanford University) and George
H. Rothblat (Children’s
Hospital of Philadelphia). The study was funded by the National
Heart, Lung, and Blood Institute and the American
PENN Medicine is
a $3.5 billion enterprise dedicated to the related missions
of medical education, biomedical research, and excellence in
patient care. PENN Medicine consists of the University of Pennsylvania
School of Medicine (founded in 1765 as the nation's first medical
school) and the University of Pennsylvania Health System.
Penn's School of Medicine is currently ranked #3 in the
nation in U.S.News & World Report's survey of top research-oriented
medical schools; and, according to most recent data from the
National Institutes of Health, received over $379 million in
NIH research funds in the 2006 fiscal year. Supporting 1,400
fulltime faculty and 700 students, the School of Medicine is
recognized worldwide for its superior education and training
of the next generation of physician-scientists and leaders of
The University of Pennsylvania Health System includes
three hospitals — its flagship hospital,
the Hospital of the University of Pennsylvania, rated one of
the nation’s “Honor Roll” hospitals by U.S.News & World
Report; Pennsylvania Hospital, the nation's first hospital; and
Penn Presbyterian Medical Center — a
faculty practice plan; a primary-care provider network; two multispecialty
satellite facilities; and home care and hospice.
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $6.7 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $392 million awarded in the 2016 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center -- which are recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report -- Chester County Hospital; Lancaster General Health; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2016, Penn Medicine provided $393 million to benefit our community.